Incivek Sales Continue To Crater, CF Program Takes The Stage At Vertex
This article was originally published in The Pink Sheet Daily
Vertex’s longer-term strategy in hepatitis C centers on combination trials of Phase II nucleoside VX-135 with three other companies’ candidates. In cystic fibrosis, Kalydeco sales continue to grow as the firm advances other candidates for combination therapy.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.